R&D channel feed

Mer­ck KGaA teams up with Ital­ian on­col­o­gy group in PARP1 de­vel­op­ment deal

3 years ago
Deals

With back-to-back PhI­II wins, Paci­ra guns for ex­pand­ed in­di­ca­tion for post-surgery pain drug Ex­par­el

3 years ago

Four years in the mak­ing, Ab­b­Vie and Cal­i­br pro­vide first look in­to ‘switch­able’ CAR-T pro­gram

3 years ago
Cell/Gene Tx

A year af­ter em­bark­ing on a new HQ and man­u­fac­tur­ing site, Ab­Cellera starts sec­ond phase of its build­out

3 years ago
Manufacturing

Take­da punts dis­ap­point­ing late-stage Mil­len­ni­um drug for $7M in cash

3 years ago

In wake of safe­ty scare, Mer­ck scraps month­ly PrEP plans for lead HIV drug — while march­ing ahead with re­vised clin­i­cal plans

3 years ago

In one-year up­date, Alzheon goes big talk, but shows off lit­tle clin­i­cal da­ta

3 years ago

Long af­ter first nod for in­haled Ty­va­so, Unit­ed Ther­a­peu­tics scraps PhI­II in PH with COPD

3 years ago
Pharma

Ahead of FDA fil­ing, Sage and Bio­gen tout more da­ta in hopes of al­le­vi­at­ing dura­bil­i­ty con­cerns

3 years ago

Blam­ing Covid-19 for ini­tial da­ta is­sues, an­tivi­ral biotech re­ports PhI­Ib fi­bromyal­gia fail — shares tank

3 years ago

Ven­tyx seeks to rack up $176M+ in its lat­est move as the mar­ket be­come bull­ish on TYK2

3 years ago
Financing

First the US, now the EU: Pfiz­er’s 20-va­lent pneu­mo­coc­cal jab for in­fants head­ed to reg­u­la­tors 

3 years ago
Pharma

Along­side promis­ing first HAE da­ta, In­tel­lia posts read­out in Re­gen­eron-part­nered AT­TR pro­gram

3 years ago

Pal­isade Bio is the lat­est to re­struc­ture, hun­ker­ing down on its lead pro­gram

3 years ago
People

In­tel­lia presents a promis­ing snap­shot of its first da­ta for once-and-done in vi­vo CRISPR treat­ment for HAE

3 years ago

Catch­ing up with Mer­ck in ad­ju­vant melanoma, Bris­tol My­ers bur­nish­es Op­di­vo pro­file in ear­li­er stages of can­cer

3 years ago
Pharma

That $930M drug Alex­ion bought to pair with Soliris, Ul­tomiris? As­traZeneca says it just aced a PhI­II test

3 years ago

NIH pumps $130M in­to health and med­i­cine AI re­search

3 years ago

Eloxx re­ports PhII cys­tic fi­bro­sis fail as the biotech weighs its op­tions

3 years ago

Up­dat­ed: Striv­ing for 2023 launch, Pfiz­er touts topline PhI­II win for an­oth­er mass mar­ket vac­cine

3 years ago

'Pluck­ing our way up that list': Bay­er high­lights on­col­o­gy am­bi­tions in new Kendall Square labs

3 years ago
Pharma

Cardiff drops its prostate can­cer pro­gram, send­ing shares in­to a tail­spin

3 years ago

CSL takes the wraps off a big new R&D cen­ter as it eyes vac­cines, cell and gene ther­a­pies

3 years ago
Pharma

'Re­al­ly in­clude every­one in the tri­al': A Q&A with the pro­to­col chair of the PhI­II mon­key­pox an­tivi­ral study

3 years ago
Pharma
FDA+
First page Previous page 118119120121122123124 Next page Last page
A service from the Financial Times